Relationship between oral contraceptive therapy and estrogen receptor status in patients with breast cancer

Anticancer Research

Volumn 28, Issue 1 B, 2008, Pages 491-493

  Lumachi, Franco ^a   Ermani, Mario ^a   Marino, Filippo ^a   Di Cristofaro, Loretta ^a   Tombolan, Valeria ^a   Brunello, Antonella ^b   Roma, Anna ^b   Basso, Umberto ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

Breast cancer; Estrogen receptor; Oral contraceptives; Progesterone receptor; Risk factors

Indexed keywords

ESTROGEN RECEPTOR; ORAL CONTRACEPTIVE AGENT; PROGESTERONE RECEPTOR;

ADULT; AGE DISTRIBUTION; AGED; BREAST CANCER; BREAST FEEDING; CANCER PATIENT; CANCER STAGING; CONFERENCE PAPER; CONTROLLED STUDY; ESTROGEN THERAPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MENARCHE; MENOPAUSE; PREGNANCY; PRIORITY JOURNAL; SPONTANEOUS ABORTION; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CONTRACEPTIVES, ORAL, HORMONAL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 40549144829     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (17)

1. Armstrong K, Eisen A and Weber B: Assessing the risk of breast cancer. N Engl J Med 342: 564-517, 2000.
2. Lumachi F, Ermani M, Brandes AA, Basso SM, Vastola F, Lonardi S and Boccagni P: Prevalence of breast cancer in women with breast complaints. Retrospective analysis in a population of symptomatic patients. Anticancer Res 22: 3777-3780, 2002.
3. Rossouw JE, Anderson GL, Prentice RL, La Croix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotvhen JM, Ockene J; Writing Group for Women's Health Initiative Investigators: Risk and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288: 321-333, 2002.
4. King WJ and Greene GL: Monoclonal antibodies localize oestrogen receptor in the nuclei of target cells. Nature 307: 745-747, 1984.
5. Harvey JM, Clark GM, Osborne CK and Allred DC: Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17: 1474-1481, 1999.
6. Jemal A, Siegel R, Ward E, Muttay T, Xu J, Smigal C and Thun MJ: Cancer statistics, 2006. CA Cancer J Clin 56: 106-130, 2006.
7. Kirsh V and Kreiger N: Estrogen and estrogen-progestin replacement therapy and risk of postmenopausal breast cancer in Canada. Cancer Causes Control 13: 583-590, 2002.
8. Li CI, Malone KE, Porter PL, Weiss NS, Tang M-TC, Cushing-Haughen KL and Daling JR: Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA 289: 3254-3263, 2003.
9. Chen WY, Hankinson SE, Schnitt SJ, Rosner BA, Holmes MD and Colditz GA : Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma. Cancer 101: 1490-1500, 2004.
10. Potter JD, Cerhan JR, Sellers TA, McGovern PG, Drinkard C, Kushi LR and Folsom AR: Progesterone and estrogen receptors and mammary neoplasia in the Iowa Women's Health Study: how many kinds of breast cancer are there? Cancer Epidemiol Biomarkers Prev 4: 319-326, 1995.
11. Yoo KY, Tajima K, Miura S, Takeuci T, Hirose K, Risch H and Dubrow R: Breast cancer risk factors according to combined estrogen and progesterone receptor status: a case-control study. Am J Epidemiol 146: 307-314, 1997.
12. Huang WY, Newman B, Millikan RC, Schell MJ, Hulka BS and Moorman PG: Hormone-related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status. Am J Epidemiol 151: 703-714, 2000.
13. Lumachi F, Basso SM, Brandes AA, Pagano D and Ermani M: Relationship between tumor markers CEA and CA 15-3, TNM staging, estrogen receptor rate and MIB-1 index in patients with pT1-2 breast cancer. Anticancer Res 24: 3221-3224, 2004.
14. Lumachi F, Ermani M, Brandes AA, Basso U and Boccagni P: Predictive value of different prognostic factors in breast cancer recurrences: multivariate analysis using a logistic regression model. Anticancer Res 21: 4105-4108, 2001.
15. Lumachi F and Basso SMM: Serum tumor markers in patients with breast cancer: Expert Rev Anticancer Ther 4: 89-99, 2004.
16. ASCO Expert Panel: 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19: 1865-1878, 2001.
17. Lower EE, Blau R, Gazder P and Stahl DL: The effect of estrogen usage on the subsequent hormone receptors status of primary breast cancer. Breast Cancer Res Treat 58: 205-211, 1999.